StockGlow

Orexo AB (ORX.ST)

Makes medications for opioid addiction, cancer pain, and overdose emergencies.

14.50-0.04%Healthcare
Compare ORX.ST with
StockGlow Score
20
Leaning Bearish
BearishBullish
1 year ago-29.3%

The outlook

Orexo trades near its 52-week low, well below both its 50- and 200-day moving averages, signaling a weak recent trend. Analyst coverage shows an average price target about 83% above the current level, though the overall sentiment leans bearish. The stock sits near the bottom of its yearly range.

What’s behind the score

Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +83% vs current price
Market cap
—
52-wk high
43.40
52-wk low
14.04
50-day avg
20.55
200-day avg
24.50
Trailing P/E
—

Similar stocks

BINV.STBioInvent International AB (publ)$23.10-1.07%SOBI.STSwedish Orphan Biovitrum AB (publ)$475.00+1.76%CAMX.STCamurus AB (publ)$623.00-0.08%BIOA-B.STBioArctic AB (publ)$324.20+0.50%ACTI.STActive Biotech AB (publ)$5.14-0.19%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy